Profit Or Loss [Abstract]

OSE Immunotherapeutics - Filing #831399

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
Profit or loss [abstract]
Profit (loss) [abstract]
Revenue
2 227 EUR
18 302 EUR
Profit (loss) from operating activities
22 986 EUR
18 476 EUR
Finance income
2 177 EUR
2 079 EUR
Finance costs
2 412 EUR
1 624 EUR
Profit (loss) before tax
23 221 EUR
18 022 EUR
Tax expense (income)
219,000 EUR
263,000 EUR
Profit (loss)
23 003 EUR
23 003 EUR
17 760 EUR
17 760 EUR
Profit (loss), attributable to [abstract]
Profit (loss), attributable to owners of parent
23 003 EUR
17 760 EUR
Earnings per share [text block]
Earnings per share [abstract]
Earnings per share [line items]
Basic earnings per share [abstract]
Basic earnings (loss) per share
118.00
96.00
Diluted earnings per share [abstract]
Diluted earnings (loss) per share
118.00
96.00

Talk to a Data Expert

Have a question? We'll get back to you promptly.